Baxter and Kuros sign sealant agreement

Baxter international has announced that Kuros Biosurgery has signed an agreement with Baxter-owned companies allowing them exclusive rights to develop and market a range of soft and hard tissue repair products. The range will combine Baxter’s fibrin based TISEEL Fibrin Sealant and Kuros’ biologics and binding technology.

Through a long term research and development agreement the two companies have shown that combining TISEEL and Kuros binding agents can enable growth factors and other bioactive agents to be attached to fibrin and can improve the regeneration of bone and soft tissue.

“We signed this commercialization agreement based on the pre-clinical results from our original research collaboration with Kuros, which showed that Baxter’s TISSEEL combined with Kuros’ biologics has promise in enhancing the regeneration of bone and soft tissue,” said Joy Amundson, president of Baxter’s BioScience business.

“This agreement positions our BioSurgery business to enter the fast-growing orthobiologic market. In addition, the products developed under this agreement complement our current product portfolio and build on our strategy to develop surgical therapies for tissue and bone regeneration,” she added.

Kuros will receive royalties on sales as well as an initial down payment and milestone awards. The companies will continue to collaborate on phase II clinical trials while Baxter will steer phase III development and regulatory licensing.

© Adfero Ltd